Aptahem AB (publ)
Research Aptahem AB (publ) (APTA.ST) on Bullrun: market cap SEK 8.27M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPTA.ST
- ExchangeXSAT
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 8.27M
- Financial periodQ2 2026
- RevenueSEK 0
- Net income-SEK 1.35M
- Free cash flow-SEK 1.77M
Valuation Snapshot
latest market cap is SEK 8.27M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | SEK 8.27M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Aptahem AB (publ)
Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company's lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aptahem AB (publ)'s market cap?
Aptahem AB (publ)'s market capitalization is SEK 8.27M.
What does Aptahem AB (publ) do?
Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company's lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage.